Imclone Systems Inc. (IMCL) Stock Soars on Favorable Drug Results
ImClone Systems Inc. and Bristol-Myers Squibb Co. claimed Tuesday that the drug Erbitux improved the survival rate of patients with the most common type of lung cancer in a late-stage study. ImClone shares jumped 18 percent.
The drug, already approved to treat colon cancer and head and neck cancer, was given to patients with advanced, non-small cell lung cancer in combination with chemotherapy treatment. The study compared the combination to chemotherapy alone.
ImClone officials could not be reached for comment on the results. It is unclear whether the study data has been fully reviewed by the company or an independent monitor.
The drug, already approved to treat colon cancer and head and neck cancer, was given to patients with advanced, non-small cell lung cancer in combination with chemotherapy treatment. The study compared the combination to chemotherapy alone.
ImClone officials could not be reached for comment on the results. It is unclear whether the study data has been fully reviewed by the company or an independent monitor.
Labels: BMY, Bristol-Meyers Squibb, IMCL, Imclone Systems Inc.
posted by Stock Administrator @ 10:26 PM
0 Comments:
Post a Comment
<< Home